Anthivera Insider
The weekly.
One careful, research-backed dispatch a week on peptide therapy for women. Each issue cited, dated, and archived here for permanence. 2 issues published.
Latest · Issue 02hormone3 min read
Kisspeptin in perimenopause: what the 2024–2025 evidence actually shows
Kisspeptin agonists are one of the more interesting peptide candidates for perimenopausal symptom management — and one of the most overhyped on social media. Here is what the clinical record actually shows as of mid-2026, and what it does not.
Read the issue
Join Anthivera Insider.
Get the weekly issue delivered. One careful, research-backed email; unsubscribe anytime.